Skip to content
Lower risk Drug recall · FDA · Published January 5, 2024

Lupin Rifampin Capsules Recall: Subpotent Drug Risk

Lupin Pharmaceuticals recalls 150mg Rifampin Capsules (30-count) due to subpotent drug and failed impurities. Rx-only product with specific batch numbers. Contact for return instructions.

🇺🇸 FDA recall #D-0283-2024DrugLupin Pharmaceuticals ›
Take action

Contact the company

Recalling firmLupin Pharmaceuticals Inc.Harborplace Tower, 111 S Calvert St Fl 21st · Baltimore, MD 21202-6174
✎ GovInfoNow plain-language explainer

Lup: Lupin Pharmaceuticals is recalling 150mg Rifampin Capsules (30-count bottles) because they may not contain the correct amount of active ingredient and have failed quality tests. This could lead to ineffective treatment if used as prescribed. Read more at govinfonow.com/recall/32889-lupin-rifampin-capsules-recall-subpotent-drug-risk.

Source Summary by GovInfoNow · govinfonow.com/recall/32889-lupin-rifampin-capsules-recall-subpotent-drug-risk · Updated August 17, 2026 · FDA enforcement record: FDA #D-0283-2024

Cite this page

“Lupin Rifampin Capsules Recall: Subpotent Drug Risk.” GovInfoNow, updated August 17, 2026. https://govinfonow.com/recall/32889-lupin-rifampin-capsules-recall-subpotent-drug-risk. Based on FDA recall #D-0283-2024 (https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0283-2024%22&limit=1).

The FDA announced on Jan. 5, 2024, that Lupin Pharmaceuticals Inc. is recalling Rifampin Capsules USP 150mg due to subpotent drug and failed impurities specifications. The voluntary Class II recall affects 15,576 bottles distributed to wholesale accounts.

How to tell if you have it

  • Brand: Lupin Pharmaceuticals
  • Product: Rifampin Capsules USP 150mg, 30-count bottle
  • NDC: 68180-658-06
  • Lot codes: A200816 (exp 1/2024), A201248 (exp 3/2024)
  • Quantity: 15,576 bottles

The hazard

The recall is due to the product being subpotent and failing impurities or degradation specifications. The FDA classified this as a Class II recall.

Context

GovInfoNow's records show Lupin Pharmaceuticals Inc. has had 90 other recalls since Jan. 31, 2013. Recent brand recalls include a Lupin Clobetasol Cream recall on Aug. 3, 2026, for failed content uniformity, and a Lupin Glucagon Emergency Kit recall on June 23, 2026, for CGMP deviation risk. Other recent recalls of similar products include Sun Pharmaceutical Lisdexamfetamine Capsules Recall (Oct. 28, 2025), Unichem busPIRone 5mg Tablets Recall (April 13, 2026), and Bell Pharmaceuticals Clinere Carbamide Peroxide Recall (June 25, 2026).

How to tell if you have this one

Check for the 30-count bottle labeled 'Rifampin Capsules USP 150mg', Rx Only. Look for batch numbers A200816 (exp 1/2024) or A201248 (exp 3/2024) on the packaging.

  • Brand
    Lupin Pharmaceuticals
  • Category
    Drug
FDA recall event · 2 products

All 2 products in this recall

FDA lists each product line separately under one recall event. Check your product description, lot or code numbers against each row. Every row shares the hazard and remedy on this page.

  • Classification
    Class II
  • Status
    Terminated
  • Distribution
    Product was distributed to 32 Wholesale/distributor accounts who further distributed the product to 156 distribution sites.
  • NDC
    68180-658-06, 68180-658-01, 68180-659-06, 68180-659-07, 68180-659-01
Recall numberProduct, codes & lotsQuantity
D-0283-2024Rifampin Capsules USP 150mg, 30-count bottle, Rx Only, Manufactured for: Lupin Pharmaceuticals, Inc. Baltimore, Maryland 21202 United States, Manufactured Lupin Limited, Aurangabad 431 210 INDIA, NDC 68180-658-06; A200816 exp 1/2024 A201248 exp 3/202415,576 Bottles
D-0284-2024Rifampin Capsules USP 300mg, 30-count bottle, Rx Only, Manufactured for: Lupin Pharmaceuticals, Inc. Baltimore, Maryland 21202 United States, Manufactured Lupin Limited, Aurangabad 431 210 INDIA, NDC 68180-659-06; A200817 exp 1/2024165,60 bottles
Based on the official FDA remedy

What to do — step by step

  1. Check Product Details

    Verify the bottle has 30 capsules labeled 'Rifampin Capsules USP 150mg, Rx Only' with batch numbers A200816 or A201248.

How this recall unfolded

Recall timeline

FDA terminated this recall 8 months after the firm started it.

1. Firm started the recall: Jan 5, 202412. FDA classified it Class II: Jan 30, 202423. Published in FDA’s Enforcement Report: Feb 7, 202434. FDA terminated the recall: Aug 27, 202442024
  1. Firm started the recall
  2. FDA classified it Class II
  3. Published in FDA’s Enforcement Report
  4. FDA terminated the recall

Dates from the agency record only; steps without a date are left out.

Similar recalls

Other Lupin Pharmaceuticals recalls

Latest drug recalls

Keep exploring

Where this comes from

The facts (hazard, remedy, dates, manufacturer) are pulled from the official FDA recall record. The plain-language summary and step-by-step checklist are written by GovInfoNow to make the official notice easier to act on — they don’t replace it.

  • Official source: FDA Recall #D-0283-2024 (January 5, 2024) — FDA publishes no per-recall page; this is the official machine-readable enforcement record. Search FDA recalls for D-0283-2024 to see it in context.
  • Plain-language summary written by qwen3:4b on August 17, 2026, from the official record above. Not reviewed by a person — if it conflicts with the FDA notice, the notice is correct. Report an error on this page.
  • GovInfoNow is an independent service and is not a government agency. We republish official FDA recall data; we don’t issue, amend or administer recalls.
GovInfoNow is an independent guide. We are not FDA or any government agency. Always confirm details with the official recall.Data: CPSC · FDA · NHTSA · USDA